U.S. Markets closed
  • S&P Futures

    4,109.25
    -13.75 (-0.33%)
     
  • Dow Futures

    33,881.00
    -115.00 (-0.34%)
     
  • Nasdaq Futures

    13,165.00
    -47.00 (-0.36%)
     
  • Russell 2000 Futures

    2,201.60
    -6.30 (-0.29%)
     
  • Crude Oil

    64.72
    -0.77 (-1.18%)
     
  • Gold

    1,869.80
    +1.80 (+0.10%)
     
  • Silver

    28.15
    -0.19 (-0.66%)
     
  • EUR/USD

    1.2232
    +0.0006 (+0.0489%)
     
  • 10-Yr Bond

    1.6420
    +0.0020 (+0.12%)
     
  • Vix

    21.34
    +1.62 (+8.22%)
     
  • GBP/USD

    1.4188
    +0.0001 (+0.0057%)
     
  • USD/JPY

    108.9400
    +0.0500 (+0.0459%)
     
  • BTC-USD

    40,625.52
    -4,207.17 (-9.38%)
     
  • CMC Crypto 200

    1,122.67
    -130.47 (-10.41%)
     
  • FTSE 100

    7,034.24
    +1.39 (+0.02%)
     
  • Nikkei 225

    27,972.86
    -433.98 (-1.53%)
     

Recap: Avid Bioservices Q2 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Avid Bioservices (NASDAQ:CDMO) moved higher by 8.2% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 133.33% over the past year to $0.01, which beat the estimate of ($0.06).

Revenue of $21,064,000 up by 15.02% from the same period last year, which beat the estimate of $15,490,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Dec 02, 2020

View more earnings on CDMO

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/jok7k959

Price Action

Company's 52-week high was at $9.37

52-week low: $3.02

Price action over last quarter: Up 11.76%

Company Profile

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.